• Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines
  • New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos
  • Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities